The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win
Source: Streetwise Reports (07/10/2026)

Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.

Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity
Source: Streetwise Reports (07/07/2026)

Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew
Source: Streetwise Reports (07/07/2026)

BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst
Source: Streetwise Reports (07/06/2026)

Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.

Satellos Bioscience Fast Track Win Fuels DMD Hopes
Source: Streetwise Reports (07/02/2026)

Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now.